Vivoryon Therapeutics N.V.

LSE:0R3M Stock Report

Market Cap: €54.3m

Vivoryon Therapeutics Valuation

Is 0R3M undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Book vs Peers

  • Price-To-Book vs Industry

  • Price-To-Book vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 0R3M when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate 0R3M's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate 0R3M's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 0R3M?

Key metric: As 0R3M is unprofitable and pre-revenue we use its Price-To-Book Ratio for relative valuation analysis.

The above table shows the Price to Book ratio for 0R3M. This is calculated by dividing 0R3M's market cap by their current book value.
What is 0R3M's PB Ratio?
PB Ratio3.9x
Book€13.98m
Market Cap€54.35m

Price to Book Ratio vs Peers

How does 0R3M's PB Ratio compare to its peers?

The above table shows the PB ratio for 0R3M vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PBEstimated GrowthMarket Cap
Peer Average3x
OPTI OptiBiotix Health
1.8xn/aUK£13.0m
ETX e-therapeutics
1.9xn/aUK£52.6m
TRX Tissue Regenix Group
1.8x170.8%UK£42.7m
HEMO Hemogenyx Pharmaceuticals
6.7xn/aUK£20.4m
0R3M Vivoryon Therapeutics
3.9x5.1%€54.3m

Price-To-Book vs Peers: 0R3M is expensive based on its Price-To-Book Ratio (3.9x) compared to the peer average (3x).

Price to Book Ratio vs Industry

How does 0R3M's PB Ratio compare vs other companies in the GB Biotechs Industry?

4 CompaniesPrice / BookEstimated GrowthMarket Cap
DEST Destiny Pharma
0.3x-15.5%US$5.85m
BDRX Biodexa Pharmaceuticals
0.5xn/aUS$4.42m
LLAI LungLife AI
0.4x101.0%US$3.40m
VAL ValiRx
0.6xn/aUS$2.81m
No more companies available in this PB range
0R3M 3.9xIndustry Avg. 2.7xNo. of Companies7PB02.44.87.29.612+
4 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Book vs Industry: 0R3M is expensive based on its Price-To-Book Ratio (3.9x) compared to the UK Biotechs industry average (2.7x).

Price to Book Ratio vs Fair Ratio

What is 0R3M's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

0R3M PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio3.9x
Fair PB Ration/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate 0R3M's Price-To-Book Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 0R3M forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current€2.11
€23.23
+1,001.1%
112.2%€60.00€2.50n/a3
Nov ’25€2.31
€23.23
+908.0%
112.2%€60.00€2.50n/a3
Oct ’25€2.32
€23.23
+901.4%
112.2%€60.00€2.50n/a3
Sep ’25€2.17
€31.25
+1,340.1%
92.0%€60.00€2.50n/a2
Aug ’25€2.33
€31.25
+1,241.2%
92.0%€60.00€2.50n/a2
Jul ’25€1.88
€41.57
+2,106.3%
69.6%€64.00€0.70n/a3
Jun ’25€2.38
€41.57
+1,646.5%
69.6%€64.00€0.70n/a3
May ’25€0.64
€41.57
+6,425.4%
69.6%€64.00€0.70n/a3
Apr ’25€0.53
€41.57
+7,728.0%
69.6%€64.00€0.70n/a3
Mar ’25€8.48
€51.63
+508.8%
39.5%€66.00€16.50n/a4
Feb ’25€8.36
€39.50
+372.5%
65.1%€64.00€1.00n/a5
Jan ’25€8.15
€39.50
+384.7%
65.1%€64.00€1.00n/a5
Dec ’24€7.62
€39.50
+418.4%
65.1%€64.00€1.00n/a5
Nov ’24€7.67
€39.50
+415.1%
65.1%€64.00€1.00€2.315
Oct ’24€11.35
€60.00
+428.6%
5.4%€64.00€56.00€2.323
Sep ’24€12.50
€60.00
+380.0%
5.4%€64.00€56.00€2.173
Aug ’24€13.49
€52.67
+290.4%
14.7%€60.00€42.00€2.333
Jul ’24€12.32
€52.67
+327.5%
14.7%€60.00€42.00€1.883
Jun ’24€14.26
€52.67
+269.2%
14.7%€60.00€42.00€2.383
May ’24€13.46
€47.67
+254.2%
18.3%€60.00€41.00€0.643
Apr ’24€15.21
€47.67
+213.3%
18.3%€60.00€41.00€0.533
Mar ’24€14.91
€47.67
+219.8%
18.3%€60.00€41.00€8.483
Feb ’24€13.84
€47.67
+244.4%
18.3%€60.00€41.00€8.363
Jan ’24€10.41
€50.00
+380.3%
20.0%€60.00€40.00€8.152
Dec ’23€10.05
€50.00
+397.4%
20.0%€60.00€40.00€7.622
Nov ’23€8.52
€50.00
+486.9%
20.0%€60.00€40.00€7.672

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

hVIVO

UK£161.9m

Operates as a pharmaceutical service and contract research company in the United Kingdom.

HVO

UK£0.24

7D

-20.1%

1Y

31.3%

Regeneron Pharmaceuticals

US$82.0b

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide.

0R2M

US$741.73

7D

-9.3%

1Y

-6.8%

Laboratorios Farmaceuticos Rovi

€3.2b

Engages in the research, development, manufacture, and marketing of pharmaceutical products in Spain and internationally.

0ILL

€61.60

7D

-5.5%

1Y

17.9%